Sensei Biotherapeutics (Sensei Biotherapeutics) Price-to-Tangible-Book : 0.58 (As of May. 11, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Price-to-Tangible-Book?

As of today (2024-05-11), Sensei Biotherapeutics's share price is $1.51. Sensei Biotherapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.59. Hence, Sensei Biotherapeutics's Price to Tangible Book Ratio of today is 0.58.

The historical rank and industry rank for Sensei Biotherapeutics's Price-to-Tangible-Book or its related term are showing as below:

SNSE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.27 Med: 0.44 Max: 1.21
Current: 0.58

During the past 6 years, Sensei Biotherapeutics's highest Price to Tangible Book Ratio was 1.21. The lowest was 0.27. And the median was 0.44.

SNSE's Price-to-Tangible-Book is ranked better than
92.71% of 1221 companies
in the Biotechnology industry
Industry Median: 2.7 vs SNSE: 0.58

A closely related ratio is called PB Ratio. As of today, Sensei Biotherapeutics's share price is $1.51. Sensei Biotherapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.59. Hence, Sensei Biotherapeutics's P/B Ratio of today is 0.58.

Sensei Biotherapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Sensei Biotherapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Price-to-Tangible-Book Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

1.21

0.44

0.27

Sensei Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial														0.44	0.49	0.38	0.28	0.27

Competitive Comparison of Sensei Biotherapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Sensei Biotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sensei Biotherapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's Price-to-Tangible-Book falls into.

Sensei Biotherapeutics Price-to-Tangible-Book Calculation

Sensei Biotherapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	1.51	/	2.593
	=	0.58

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Sensei Biotherapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

407:Germany 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Executives

Stephanie Krebs	officer: Chief Business Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi	director, officer: President & CEO	SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer	director, 10 percent owner	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc	10 percent owner, other: See Remarks	228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd.	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p.	other: See Explanation of Responses	340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c.	10 percent owner	340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher	officer: Chief Business Officer	66 HAROLD ST, BOSTON MA 02119
William R Ringo	director
Thomas G Ricks	director	H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer	director	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English	director	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850